The EUMCA: Pioneering access to medicinal cannabis – via Open Access Government

“Patients should have the right to know what they are buying or being prescribed is of proper quality. Currently, there is no real agreement on what analytical methodology should be used to check the quality nor what standards we should set, for instance, for CBD.

My request of Europe, will be that can we all agree at least what analytical methods should be the standard by which we judge the quality of these products?”

Professor Trevor Jones, Chair at the European Medicinal Cannabis Association (EUMCA), speaks to Nishat about their plans for EU patient access to medicinal cannabis

When I spoke to Professor Trevor Jones on an unassumingly rainy day, it was just before noon. We immediately begun to discuss the indecipherable amount of activity related to medicinal cannabis, and drug development precedents set in the past.

What are countries doing about legality and production? What is the general consensus on a globalised level about what to do next? Where is the line between hype and functional reality?

Countless experts can theorise on how these negotiations of permissibility will go. With his decades-long experience in biotech, the pharmaceutical industry and academia, Professor Trevor Jones is well-poised to give us some grounded explanations. 

Full Open Access Governement interview here


For further information, please contact:

SENSO Communications
Penny Lukats, 07775992350,

For more information on the EUMCA ( and membership, please contact:
Sita Schubert, General Secretary of the EUMCA on +32 233 90 281,



The EUMCA is the first international non-profit association governed by the provisions of the Belgian Code des Sociétés et des Associations. Its membership is a multi-stakeholder network representing the interests of a wide range of organisations operating in the research and development, production and/or distribution of medical cannabis-based treatments.

The EUMCA’s mission is to improve the life and health outcomes of patients across Europe, by promoting the development of national government healthcare policies that advocate i) the ethical prescription of pharmaceutical-grade medicinal cannabis, and ii) advance patient access to treatments. It does this through:

  • Research & Development: Promoting scientific medical research and policy to support the standardised, ethical and sustainable use of medicinal cannabis.
  • Patient Access & Reimbursement: Working with national reimbursement institutions to improve patient access to medical cannabis-based treatments.
  • Medical Education: Providing evidence-based knowledge and learning on medicinal cannabis to healthcare professionals and patients.
  • Legal & Compliance: Consulting with governments where ongoing or urgent action is necessary.
  • Regulatory & Quality: Providing members with counsel and guidance on regulatory affairs.
  • Business Development: Delivering networking opportunities for members focused on building their business through M&A, licensing, partnering and novel in-market strategies.